office in New York City. Highlights of the Company include:

- World Class Partnerships: Partnered/affiliated with leading research institutions and practitioners including the Brain Trauma Foundation (“BTF”), Stanford University, Mass General Hospital and the Pac-12.

- Millions in R&D: SyncThink and BTF have successfully secured over $36 million in technology development and research contracts from US Department of Defense since 2008.

- Numerous Applications with FDA Approval: Initial focus on neuro-diagnostics (primarily concussions) in military and athletics. Broader set of potential applications include attention development in children,, enhancing brain performance, fatigue evaluation, pharmacuetical, among others. The EYE-SYNC device has been FDA approved.

- Proprietary Software Technology: Eleven issued patents (with additional six patents pending) covering hardware, analytics, market applications and scientific platform.

TECHNOLOGY

The EYE-SYNC device is a fully-integrated, head-mounted eye-tracking device for rapid, reliable screening of attention focus. The device is non-invasive, low-risk, and highly reliable. As a subject tracks a predictable moving target that follows a circular trajectory on a screen within the head mounted device, eye movements are recorded by high speed cameras. Embedded systems software characterizes eye-target synchronization and the results are displayed and stored on a handheld peripheral for instant concussion screening. The benefits of the EYE-SYNC technology are speed (takes less than 60 seconds), accuracy, portability, and proven metrics.